EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions

Ximena Parraga iD, Eyad Abdulrazzak iD, Ritah R Chumdermpadetsuk iD, Marwan Alsaqa iD, Shanmukh Pavan Lingamsetty iD, Alan Bonder iD, Behnam Saberi iD

Journal of Clinical Medicine · 03.10.2025 · 14 (19) · 7009

DOI: 10.3390/jcm14197009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.10.2025. Verfasst von Ximena Parraga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a leading cause of cancer death, with liver transplantation (LT) offering a curative option for early-stage patients who cannot undergo resection. Although LT provides good long-term outcomes within standard criteria, recurrence occurs in approximately 8–20% of recipients and often leads to poor survival. Traditionally, LT eligibility relied on strict criteria like the Milan criteria, which are effective in selecting patients with low recurrence but may exclude patients who could benefit from transplantation. In response, new expanded criteria and models using tumor biology have been developed for better risk stratification, allowing more personalized selection and management. Despite these advances, recurrence remains a major clinical challenge, with no consensus on optimal imaging timing or frequency post-LT. Treatment depends on the recurrence’s extent and location, including surgical resection and locoregional therapies. Systemic treatments are promising, especially for unresectable or extrahepatic recurrence, though most evidence comes from small retrospective studies, limiting the development of standardized protocols. Future research should focus on addressing these gaps and guiding evidence-based post-transplant care. This is a narrative review summarizing recent advances in HCC recurrence.

Schlagwörter

Stichwörter der Autor:innen

hepatocellular carcinomaimmunotherapyliver transplantationrecurrence

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Division of Transplantation, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Division of Internal Medicine, Saint Peter's University Hospital, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.

ORCID-Profile: Ximena Parraga, Eyad Abdulrazzak, Ritah R Chumdermpadetsuk, Marwan Alsaqa, Shanmukh Pavan Lingamsetty, Alan Bonder, Behnam Saberi

Zitieren

APA

Parraga, X., Abdulrazzak, E., Chumdermpadetsuk, R. R., Alsaqa, M., Pavan Lingamsetty, S., Bonder, A., & Saberi, B. (2025). Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions. Journal of Clinical Medicine, 14(19), 7009. https://doi.org/10.3390/jcm14197009

Vancouver

Parraga X, Abdulrazzak E, Chumdermpadetsuk RR, Alsaqa M, Pavan Lingamsetty S, Bonder A, et al. Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions. Journal of Clinical Medicine. 2025;14(19):7009. doi:10.3390/jcm14197009

BibTeX
@article{Parraga2025,
  author = {Parraga, Ximena and Abdulrazzak, Eyad and Chumdermpadetsuk, Ritah R and Alsaqa, Marwan and Pavan Lingamsetty, Shanmukh and Bonder, Alan and Saberi, Behnam},
  title = {Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {19},
  pages = {7009},
  doi = {10.3390/jcm14197009}
}
Kostenlos starten →